NASDAQ
116.68USD
+0.19 (+0.16%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
781.6M
P/E
—
EPS
—
Beta
1.51
52W range
29.18-124.82
Day range
114.11–117.99
Open
116.65
Prev close
116.49
Volume
79.6K
Avg volume
207.1K
Dividend
0.00
IPO
2019-12-19
https://seekingalpha.com/article/4937793-monopar-licensing-agreement-and-rolling-nda-submission-serve-as-catalysts-for-strong-buy · 8/18/2026+1.00
https://seekingalpha.com/article/4922860-monopar-a-rare-disease-asset-with-heavy-metal-upside-initiating-buy · 7/17/2026+1.00
https://www.globenewswire.com/news-release/2026/04/19/3276675/0/en/Monopar-Presents-Phase-3-Data-Showing-Greater-Neurologic-Benefit-with-ALXN1840-vs-SoC-in-Wilson-Disease-Patients-with-Neurologic-Symptoms-at-AAN-2026.html · 4/19/2026+1.00
https://www.globenewswire.com/news-release/2025/11/09/3184138/0/en/Monopar-Presents-New-Data-and-Analyses-on-Rapidly-Improved-Copper-Balance-in-Wilson-Disease-Patients-on-Tiomolybdate-Choline-at-AASLD-The-Liver-Meeting-2025.html · 11/9/2025+0.80
https://www.defenseworld.net/2025/10/26/monopar-therapeutics-inc-nasdaqmnpr-given-average-rating-of-buy-by-analysts.html · 10/26/2025+0.80
https://www.zacks.com/stock/news/2773124/does-monopar-therapeutics-mnpr-have-the-potential-to-rally-42-46-as-wall-street-analysts-expect?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2773124 · 10/21/2025+0.80
https://www.globenewswire.com/news-release/2025/09/24/3155163/0/en/Monopar-Therapeutics-Inc-Announces-Pricing-of-135-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html · 9/24/2025+0.40
https://www.globenewswire.com/news-release/2025/09/24/3155162/0/en/Monopar-Announces-Journal-of-Hepatology-Publishes-Physicians-Letter-to-the-Editor-Demonstrating-ALXN1840-Rapidly-Improved-Copper-Balance-in-Wilson-Disease-Patients.html · 9/24/2025+0.80
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
